NousCom is a biotech company founded by experienced entrepreneurs who are developing innovative immunotherapies to combat cancer by activating cancer-specific T cells.
NousCom strategy stems from recent achievements in the fields of checkpoint inhibitors, therapeutic antibodies, cancer vaccines and oncolytic viruses.
We plan to develop a series of new, potent immunotherapeutics capable of selectively killing tumor cells, with the expectation to potentiate existing immunotherapies.
Our platform technology is based on three different viral vectors as a powerful toolkit to induce broad and potent anti-cancer T cell responses.